Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) filed this Form 8-K on October 2, 2025, reporting a corporate governance event regarding its stock listing status. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on listing status and compliance with Nasdaq rules.
Material Changes
- Listing Transfer: Nasdaq approved the transfer of XLO's common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective October 6, 2025.
- Trading Symbol: The stock will continue to trade under the symbol "XLO".
- Compliance Status: The transfer follows a notification on April 8, 2025, regarding the company's failure to maintain the $1.00 minimum bid price required for the Global Select Market.
Outlook, Risks, and Contingencies
Grace Period: Nasdaq granted the company an additional 180-day period, extending until March 30, 2026, to regain compliance with the $1.00 minimum bid price requirement.
Compliance Criteria: To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days during the grace period.
Management Action: The company is evaluating available options to meet the minimum bid price requirement. Failure to comply by the deadline could result in delisting.
Investor Verification Checklist
- Verify the effective date of the listing transfer (October 6, 2025) and confirm trading continues under symbol "XLO".
- Monitor the stock price to track progress toward the $1.00 minimum bid price requirement.
- Review the March 30, 2026 deadline for regaining compliance to assess delisting risk.
- Check for future announcements regarding specific strategies the company is employing to increase its share price.